Newborn screening (NBS) is a vital public health initiative aimed at detecting congenital disorders in infants shortly after birth. Through blood tests, NBS identifies conditions like phenylketonuria, cystic fibrosis, and sickle cell disease, enabling early intervention and treatment to prevent severe health complications, ensuring a healthier start to life.
Newborn screening (NBS) companies in India are revolutionizing solutions delivery by employing state-of-the-art technologies and innovative methodologies. These forward-thinking firms are streamlining processes, enhancing accuracy, and expanding accessibility to NBS services nationwide. Through their groundbreaking efforts, they’re safeguarding infant health, catalyzing early interventions, and setting new standards in newborn care across India.
Life cell
Founded in 2004, LifeCell stands as the nation’s premier stem cell and tissue storage bank, leading the frontier in genetic screening tests and advancing cell and tissue-based therapeutics. LifeCell harnesses the potential of Cellular, Genetic, and Tissue Sciences to deliver cutting-edge products and solutions that not only meet present healthcare demands but also anticipate future challenges. They’ve achieved a remarkable >97% likelihood of securing a stem cell transplant match for individuals of Indian descent. Additionally, leading the nation in providing rapid genomic testing results, crucial particularly in pregnancies and infancy where timely interventions can significantly impact health outcomes. With advancements in NGS technology, the once costly and inaccessible whole genome sequencing has become more affordable and accessible. Leveraging this progress, LifeCell has introduced GenomeScope NICU and GenomeScope Newborn. GenomeScope NICU swiftly diagnoses genetic causes behind unexplained infant illnesses in NICU admissions, while GenomeScope Newborn identifies inherited conditions before symptoms arise. With a >95% detection rate and >99% reporting accuracy, these tests streamline treatment, sparing patients unnecessary interventions and reducing hospital costs.
Trivitron Healthcare
Since its inception in 1997, Trivitron Healthcare has been a beacon of innovation in the medical technology sector, offering affordable healthcare solutions that inspire countless healthcare providers worldwide. Catering to hospitals, individual healthcare providers, independent clinics, laboratories, extended care facilities, renal care centres, and more. Trivitron’s commitment to technological advancements ensures superior clinical benefits at lower costs. Firmly believing that quality healthcare is a fundamental right, Trivitron strives to make it accessible to people of all socioeconomic backgrounds. Boasting robust research and development capabilities, Trivitron manufactures and distributes top-tier medical technology products to over 180 countries, Trivitron leads innovation in areas such as Newborn Screening, In-Vitro Diagnostics, Imaging & Radiology, Renal Care, Radiation Protection, Critical Care, and Operating Room Solutions, cementing its reputation as a comprehensive healthcare provider. Trivitron offers a diverse spectrum of newborn screening instruments, including Modular and Fully Automated NBS Instrumentation, and reagent kits. Labsystems Diagnostics, a division of Trivitron, pioneered the first fluorometric microplate-based assay for phenylalanine to diagnose phenylketonuria (PKU) in newborns. Their newborn screening products use advanced fluorescence and photometric detections, available in both manual and fully automated systems. This technology ensures high-quality and cost-effective newborn screening, crucial for early detection of metabolic disorders. Labsystems’ solutions include sophisticated fully-automated systems, LC-MS/MS kits for monitoring amino acids and acylcarnitines, and photometric assays. These comprehensive tools aid in the detection of over 50 disorders, providing vital early interventions to prevent long-term health issues in newborns. Trivitron’s product range includes assays for various disorders from dried blood spots (DBS), such as NeoScreen TSH, NeoScreen 17OHP, NeoScreen G6PD, NeoScreen Galactose, and NeoScreen IRT.
Bio-Rad Laboratories,
A prominent player in the development, manufacturing, and marketing of a diverse array of products for the life science research and clinical diagnostics markets. Headquartered in Hercules, California, Bio-Rad boasts a global network encompassing research, development, manufacturing, and sales operations. Serving a wide range of customers, including universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies, Bio-Rad is dedicated to advancing science and saving lives through innovative, high-quality products. Bio-Rad has a comprehensive range of newborn screening kits, assays, instruments, and software. The VARIANTnbs Newborn Screening System of Bio-Rad sets the global standard for automated newborn screening for sickle cell disease and other hemoglobin disorders. It tests dried blood spot specimens for abnormal hemoglobins linked to the disease, offering fully automated, high-capacity analysis. The VARIANTnbs provides the total hemoglobin picture.
PerkinElmer
PerkinElmer, a prominent global provider of analytical services and solutions, offers a range of leading services through its OneSource Field and Laboratory services division. These services support various sectors including biopharma, food, environmental, safety, and applied markets, facilitating the acceleration of scientific outcomes. Since its inception in 1937, PerkinElmer serves customers in more than 35 countries worldwide and has been a reliable partner in laboratory analysis and management. Today, the company enhances its service offerings with an extensive selection of instruments and consumables, including atomic spectroscopy, molecular spectroscopy, and chromatography products. PerkinElmer offers various technologies for newborn screening, including dried blood spot assays using time-resolved fluorometry, MS/MS, and IEF. The 1445-0020 PerkinElmer MS/MS System, featuring the Quattro micro™ tandem mass spectrometer, is designed for expanded newborn screening. For managing screening data, PerkinElmer provides Wallac Specimen Gate® software, a specialized LIMS that ensures comprehensive laboratory information and workflow management, along with seamless instrument integration.
Medtronic
Based in Dublin, Ireland, is the world’s leading healthcare technology company, committed to health issues by relentlessly pursuing innovative solutions. Medtronic brings together a global team of over 95,000 dedicated individuals across 150 countries. They offer technologies and therapies for 70 health conditions, including cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Medtronic’s Pulse Oximetry for CCHD Screening, Detects Critical Congenital Heart Disease (CCHD) with Nellcor™ pulse oximetry, reducing the risk of complications. This non-invasive, painless, and cost-effective test measures a newborn’s oxygen saturation to identify CCHD.
